Greek yogurt trial finds limited changes in bone and inflammation markers
A short pilot study in older adults found mixed blood-marker changes, leaving bone and immune health benefits uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The study reported limited, mixed blood-marker changes with Greek yogurt supplementation. A marker of bone breakdown increased among exercisers receiving yogurt, while some inflammatory markers moved in opposite directions among non-exercisers receiving yogurt. These findings do not establish improvements in bone strength or immune health.
The authors caution that pilot design and statistical constraints limit interpretation. The abstract reports biomarkers rather than fracture, bone-strength, or illness outcomes.
What researchers found
Bone-resorption marker
C-terminal telopeptide of type I collagen rose from baseline in yogurt-supplemented exercisers at week 8. This is a within-group change; the time-by-group interaction had p = 0.022.
How groups were formed
Only the exercising participants were described as randomized to yogurt or no supplement. Non-exercisers receiving yogurt formed a separate comparison group, limiting what the trial can establish about exercise itself.
Mixed biological signals
The researchers reported no detected change in body fat or tumor necrosis factor alpha. Other blood markers showed mixed responses, so individual shifts should not be treated as consistent improvement in bone or immune health.
The original publication
Effects of Greek Yogurt Supplementation and Exercise on Markers of Bone Turnover and Inflammation in Older Adult Exercisers: An 8-Week Pilot Intervention Trial.
Bell M, Narciso PH, Baker E et al.
Nutrients · 2025
- PubMed ID
- 41470847
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.